Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFolfirinox vs Gemcitabine in Resected Pancreatic Adenocarcinoma
NCT01526135Phase 3Completed
- Sponsor
- Unicancer
- Start
- Apr 2012
- Primary completion
- Mar 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of fluorouracil, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Unicancer. Started Apr 2012; status: completed.
02
Drugs
fluorouracilfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01526135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01526135.